Open AccessFocal magnetic resonance guided focused ultrasound for prostate cancer: Initial North American experience
Author(s) -
Uri Lindner,
Sangeet Ghai,
Paula Spensieri,
Eugen Hlasny,
Theodorus H. van der Kwast,
Stuart A. McCluskey,
Masoom A. Haider,
Walter Kucharczyk,
John Trachtenberg
Publication year - 2012
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.138
Subject(s) - medicine , prostate cancer , magnetic resonance imaging , ablation , prostate , radiation therapy , ultrasound , radiology , cancer , radiation treatment planning
The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression). The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).